|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.36/-0.74
|
企業價值
78.70M
|
資產負債 |
每股賬面淨值
1.12
|
現金流量 |
現金流量率
--
|
損益表 |
收益
25.98M
|
每股收益
0.47
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. |